Rituximab in adult minimal change disease and focal segmental glomerulosclerosis

Nephron - Clinical Practice

Volumn 128, Issue , 2014, Pages 277-282

  Kronbichler, Andreas ^a   Bruchfeld, Annette ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Focal segmental glomerulosclerosis; Minimal change disease; Nephrotic syndrome; Rituximab

Indexed keywords

RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; B LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; MINIMAL CHANGE GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; ADULT; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOLOGY; NEPHROSIS, LIPOID;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; NEPHROSIS, LIPOID; RITUXIMAB;

EID: 84922896237     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000368590     Document Type: Review

References (23)

1. Hogan J, Radhakrishnan J: The treatment of minimal change disease in adults. J Am Soc Nephrol 2013; 24:702-711.
2. Ponticelli C, Graziani G: Current and emerging treatments for idiopathic focal and seg-mental glomerulosclerosis in adults. Expert Rev Clin Immunol 2013; 9:251-261.
3. Ruggenenti P, Ruggiero B, Cravedi P, Vivar-elli M, Massella L, Marasa M, et al: Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 2014; 25:850-863.
4. Datta SK: Anti-CD20 antibody is an efficient therapeutic tool for the selective removal of autoreactive T cells. Nat Clin Pract Rheuma-tol 2009; 5:80-82.
5. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al: Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 2011; 3:85ra46.
6. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al: Abatacept in B7-1-positive proteinuric kidney disease. N Engl J Med 2013; 369:2416-2423.
7. Fernandez-Fresnedo G, Segarra A, Gonzalez E, Alexandru S, Delgado R, Ramos N, et al: Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulo-sclerosis. Clin J Am Soc Nephrol 2009; 4: 1317-1323.
8. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al: Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011; 117:c98-c105.
9. Kong WY, Swaminathan R, Irish A: Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol 2013; 45:795-802.
10. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83:511-516.
11. Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013; 28:1225-1232.
12. Bruchfeld A, Benedek S, Hilderman M, Me-din C, Snaedal-Jonsdottir S, Korkeila M: Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant 2014; 29:851-856.
13. El-Reshaid K, Sallam HT, Hakim AA, Al-At-tiyah R: Rituximab in treatment of idiopathic glomerulopathy. Saudi J Kidney Dis Transpl 2012; 23:973-978.
14. Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, et al: Rituximab treatment for relapsing minimal change disease and focal segmental glo-merulosclerosis: a systematic review. Am J Nephrol 2014; 39:322-330.
15. Czarniak P, Zaluska-Lesniewska I, Zagozd-zon I, Zurowska A: Difficulties in diagnosing severe Pneumocystis jiroveci pneumonia after rituximab therapy for steroid-dependent ne-phrotic syndrome. Pediatr Nephrol 2013; 28: 987-988.
16. Sellier-Leclerc AL, Belli E, Guerin V, Dorf-müller P, Deschenes G: Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013; 28:1875-1879.
17. Nazi I, Kelton JG, Larche M, Snider DP, Hed-dle NM, Crowther MA, et al: The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013; 122:1946-1953.
18. Guigonis V, Dallocchio A, Baudouin V, De-hennault M, Hachon-Le Camus C, Afanetti M, et al: Rituximab treatment for severe steroid-or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008; 23:1269-1279.
19. Sellier-Leclerc AL, Baudouin V, Kwon T, Ma-cher MA, Guerin V, Lapillonne H, et al: Ritux-imab in steroid-dependent idiopathic ne-phrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant 2012; 27:1083-1089.
20. Fervenza FC, Abraham RS, Erickson SB, Iraz-Abal MV, Eirin A, Specks U, et al: Rituximab therapy in idiopathic membranous nephrop-Athy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188-2198.
21. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al: Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoim-munity and rituximab registry. Arthritis Rheum 2010; 62:2625-2632.
22. Basu B: Ofatumumab for rituximab-resistant nephrotic syndrome. N Engl J Med 2014; 370: 1268-1270.
23. http://clinicaltrials.gov/ct2/show/NCT016104 92?term=belimumab+membranous+nephrop athy&rank=2. NLM identifier: NCT01610492.